|4Jan 30, 9:15 PM ET

Atkisson Erik 4

4 · Eiger BioPharmaceuticals, Inc. · Filed Jan 30, 2023

Insider Transaction Report

Form 4
Period: 2023-01-26
Atkisson Erik
GC & Chief Compliance Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-01-26+26,75026,750 total
    Exercise: $1.37Exp: 2033-01-26Common Stock (26,750 underlying)
Footnotes (1)
  • [F1]The option vests as to 50% on the first anniversary of the January 26, 2023 grant date, and as to the remaining 50% on June 26, 2024, subject to the Reporting Person's continuous service as of each such date. The option vests in full upon a change in control of the Issuer.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4